磷霉素
达托霉素
万古霉素
微生物学
肠球菌
抗生素
医学
抗菌剂
心内膜炎
内科学
金黄色葡萄球菌
生物
细菌
遗传学
作者
Caterina Di Cecco,Jacopo Monticelli,Stefano Di Bella,Vittorio Di Maso,Roberto Luzzati
标识
DOI:10.1080/1120009x.2023.2247205
摘要
AbstractBloodstream infections caused by vancomycin-resistant enterococci are increasingly reported and a consensus therapy does not exist. Oritavancin has shown good antimicrobial activity against VRE, but its use is mainly limited to skin, soft tissue, and/or bone infections. Fosfomycin is increasingly used for enterococcal infections (including bloodstream infections and endocarditis) as a partner drug given its anti-biofilm and synergistic properties. Recently in vitro and in vivo synergism between oritavancin and fosfomycin against VRE isolates has been demonstrated. Herein we report the case of a hematologic patient with a VRE bloodstream infection successfully treated with oritavancin and fosfomycin as sequential treatment.Keywords: Enterococcusbloodstream infectionsfosfomycinoritavancinVREoutcomehospital acquired infections Disclosure statementNo potential conflict of interest was reported by the author(s).
科研通智能强力驱动
Strongly Powered by AbleSci AI